Cynata Therapeutics' Recruitment Completion for Acute Graft Versus Host Disease Clinical Trial Provides Reference for Results Timing, Euroz Hartleys Says

MT Newswires Live12-16 11:12

Cynata Therapeutics' (ASX:CYP) completion of recruitment for its acute graft versus host disease clinical trial provides a clear line of sight to the timing of top-line results from the company's clinical program, the outcome of which is expected to be a major catalyst, Euroz Hartleys said in a note on Monday.

The company completed the enrollment of 65 patients for its phase 2 clinical trial of drug candidate, CYP-001, in adults with high-risk acute graft versus host disease.

The analysts anticipate that the firm's CYP-001 drug candidate could attract "significant" commercial interest if it successfully replicates its first phase results.

The investment firm maintained its speculative buy recommendation and AU$0.90 price target on Cynata Therapeutics.

Cynata Therapeutics' shares jumped about 4% in recent Tuesday trade and earlier hit their highest since August 2022.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591967429?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 11:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591967429","market":"sg","top_or_hot":-1,"title":"Cynata Therapeutics' Recruitment Completion for Acute Graft Versus Host Disease Clinical Trial Provides Reference for Results Timing, Euroz Hartleys Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CYP.AU\">Cynata Therapeutics</a>' (ASX:CYP) completion of recruitment for its acute graft versus host disease clinical trial provides a clear line of sight to the timing of top-line results from the company's clinical program, the outcome of which is expected to be a major catalyst, <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys said in a note on Monday.</p><p>The company completed the enrollment of 65 patients for its phase 2 clinical trial of drug candidate, CYP-001, in adults with high-risk acute graft versus host disease.</p><p>The analysts anticipate that the firm's CYP-001 drug candidate could attract \"significant\" commercial interest if it successfully replicates its first phase results.</p><p>The investment firm maintained its speculative buy recommendation and AU$0.90 price target on Cynata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>.</p><p>Cynata Therapeutics' shares jumped about 4% in recent Tuesday trade and earlier hit their highest since August 2022.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cynata Therapeutics' Recruitment Completion for Acute Graft Versus Host Disease Clinical Trial Provides Reference for Results Timing, Euroz Hartleys Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCynata Therapeutics' Recruitment Completion for Acute Graft Versus Host Disease Clinical Trial Provides Reference for Results Timing, Euroz Hartleys Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-16 11:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CYP.AU\">Cynata Therapeutics</a>' (ASX:CYP) completion of recruitment for its acute graft versus host disease clinical trial provides a clear line of sight to the timing of top-line results from the company's clinical program, the outcome of which is expected to be a major catalyst, <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys said in a note on Monday.</p><p>The company completed the enrollment of 65 patients for its phase 2 clinical trial of drug candidate, CYP-001, in adults with high-risk acute graft versus host disease.</p><p>The analysts anticipate that the firm's CYP-001 drug candidate could attract \"significant\" commercial interest if it successfully replicates its first phase results.</p><p>The investment firm maintained its speculative buy recommendation and AU$0.90 price target on Cynata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>.</p><p>Cynata Therapeutics' shares jumped about 4% in recent Tuesday trade and earlier hit their highest since August 2022.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4218","symbol_name":"酒店及度假村房地产信托","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2591967429","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591967429","pubTimestamp":1765854732,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cynata Therapeutics' (ASX:CYP) completion of recruitment for its acute graft versus host disease clinical trial provides a clear line of sight to the timing of top-line results from the company's clin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4218":"酒店及度假村房地产信托","BK4181":"酒店及度假村房地产投资信托","LENZ":"Therapeutics","BK4139":"生物科技","BK7067":"生物科技","BK7508":"医药生物股","HST":"美国豪斯特酒店","CYP.AU":"CYNATA THERAPEUTICS LTD","BK7501":"新冠治疗股","BK4007":"制药","BK4539":"次新股","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Euroz Hartleys表示，Cynata Therapeutics完成急性移植物抗宿主病临床试验的招募为结果时机提供了参考","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"HST":1.5,"CYP.AU":1},"content_text":"Cynata Therapeutics' (ASX:CYP) completion of recruitment for its acute graft versus host disease clinical trial provides a clear line of sight to the timing of top-line results from the company's clinical program, the outcome of which is expected to be a major catalyst, Euroz Hartleys said in a note on Monday.The company completed the enrollment of 65 patients for its phase 2 clinical trial of drug candidate, CYP-001, in adults with high-risk acute graft versus host disease.The analysts anticipate that the firm's CYP-001 drug candidate could attract \"significant\" commercial interest if it successfully replicates its first phase results.The investment firm maintained its speculative buy recommendation and AU$0.90 price target on Cynata Therapeutics.Cynata Therapeutics' shares jumped about 4% in recent Tuesday trade and earlier hit their highest since August 2022.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591967429","isCrawlerRequest":true}